{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T20:55:34Z","timestamp":1783976134830,"version":"3.55.0"},"reference-count":45,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100007129","name":"Natural Science Foundation of Shandong Province","doi-asserted-by":"publisher","award":["ZR2024MB112"],"award-info":[{"award-number":["ZR2024MB112"]}],"id":[{"id":"10.13039\/501100007129","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002367","name":"Chinese Academy of Sciences","doi-asserted-by":"publisher","award":["XDB1060000"],"award-info":[{"award-number":["XDB1060000"]}],"id":[{"id":"10.13039\/501100002367","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82273759"],"award-info":[{"award-number":["82273759"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82574229"],"award-info":[{"award-number":["82574229"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018537","name":"National Science and Technology Major Project","doi-asserted-by":"publisher","award":["2025ZD1800700"],"award-info":[{"award-number":["2025ZD1800700"]}],"id":[{"id":"10.13039\/501100018537","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008327","name":"Zhejiang University of Technology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008327","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011408","name":"State Key Laboratory of Medicinal Chemical Biology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011408","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011195","name":"Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011195","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.ejmech.2026.118921","type":"journal-article","created":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T22:52:42Z","timestamp":1777762362000},"page":"118921","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Discovery and characterization of YSA64, a RBM39 degrader with in vivo efficacy and potent cellular activity in pediatric Ewing sarcoma A673"],"prefix":"10.1016","volume":"314","author":[{"given":"Xilin","family":"Lyu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiyi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanyan","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiancheng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yixuan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shumeng","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Biyu","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziqin","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shijie","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhang","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"He","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1035-2272","authenticated-orcid":false,"given":"Yujun","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2026.118921_bib1","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1038\/s41583-023-00717-6","article-title":"Alternative splicing in neurodegenerative disease and the promise of RNA therapies","volume":"24","author":"Nikom","year":"2023","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.ejmech.2026.118921_bib2","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1016\/j.drudis.2019.03.030","article-title":"Alternative splicing, RNA-seq and drug discovery","volume":"24","author":"Zhao","year":"2019","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.ejmech.2026.118921_bib3","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1080\/15476286.2024.2303558","article-title":"Small molecule inhibition of RNA binding proteins in haematologic cancer","volume":"21","author":"Jaiswal","year":"2024","journal-title":"RNA Biol."},{"key":"10.1016\/j.ejmech.2026.118921_bib4","doi-asserted-by":"crossref","first-page":"16002","DOI":"10.1021\/acs.jmedchem.4c01330","article-title":"RNA-binding small molecules in drug discovery and delivery: an overview from fundamentals","volume":"67","author":"Chen","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118921_bib5","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1021\/acsmedchemlett.0c00659","article-title":"Risdiplam, the first approved small molecule splicing modifier drug as a blueprint for future transformative medicines","volume":"12","author":"Ratni","year":"2021","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2026.118921_bib6","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1016\/j.drudis.2020.12.019","article-title":"Specific and selective induction of miR-124 in immune cells by the quinoline ABX464: a transformative therapy for inflammatory diseases","volume":"26","author":"Tazi","year":"2021","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.ejmech.2026.118921_bib7","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/s41573-025-01280-8","article-title":"RNA modification systems as therapeutic targets","volume":"25","author":"Zhang","year":"2026","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejmech.2026.118921_bib8","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1038\/s41573-024-00943-2","article-title":"Frameworks for transformational breakthroughs in RNA-based medicines","volume":"23","author":"Androsavich","year":"2024","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejmech.2026.118921_bib9","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1080\/15476286.2023.2239601","article-title":"Pre-mRNA splicing-associated diseases and therapies","volume":"20","author":"Love","year":"2023","journal-title":"RNA Biol."},{"key":"10.1016\/j.ejmech.2026.118921_bib10","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1021\/acsmedchemlett.5c00424","article-title":"Discovery of the U2AF1-UHM inhibitor that possesses anti-leukemia activity in vitro","volume":"16","author":"Patil","year":"2025","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2026.118921_bib11","series-title":"Reference Module in Chemistry, Molecular Sciences and Chemical Engineering","article-title":"Medicinal chemistry approaches to modulation of splicing, RNA modifications, and RNA editing in cancer therapeutics","author":"Schirok","year":"2025"},{"key":"10.1016\/j.ejmech.2026.118921_bib12","doi-asserted-by":"crossref","DOI":"10.1126\/science.aal3755","article-title":"Anticancer sulfonamides target splicing by inducing RBM39 degradation via recruitment to DCAF15","volume":"356","author":"Han","year":"2017","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2026.118921_bib13","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/s41589-019-0411-6","article-title":"Structural basis of indisulam-mediated RBM39 recruitment to DCAF15 E3 ligase complex","volume":"16","author":"Bussiere","year":"2020","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.ejmech.2026.118921_bib14","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/s41589-019-0378-3","article-title":"Structural complementarity facilitates E7820-mediated degradation of RBM39 by DCAF15","volume":"16","author":"Faust","year":"2020","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.ejmech.2026.118921_bib15","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1038\/nchembio.2363","article-title":"Selective degradation of splicing factor CAPER\u03b1 by anticancer sulfonamides","volume":"13","author":"Uehara","year":"2017","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.ejmech.2026.118921_bib16","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.ccell.2019.01.010","article-title":"Targeting an RNA-binding protein network in acute myeloid leukemia","volume":"35","author":"Wang","year":"2019","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ejmech.2026.118921_bib17","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1158\/1078-0432.CCR-0109-03","article-title":"An angiogenesis inhibitor E7820 shows broad-spectrum tumor growth inhibition in a xenograft model: possible value of integrin alpha2 on platelets as a biological marker","volume":"10","author":"Semba","year":"2004","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejmech.2026.118921_bib18","first-page":"275","article-title":"Profiling novel sulfonamide antitumor agents with cell-based phenotypic screens and array-based gene expression analysis","volume":"1","author":"Yokoi","year":"2002","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.ejmech.2026.118921_bib19","doi-asserted-by":"crossref","first-page":"eabj5405","DOI":"10.1126\/sciadv.abj5405","article-title":"Targeting the spliceosome through RBM39 degradation results in exceptional responses in high-risk neuroblastoma models","volume":"7","author":"Singh","year":"2021","journal-title":"Sci. Adv."},{"key":"10.1016\/j.ejmech.2026.118921_bib20","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1038\/s41467-022-28907-3","article-title":"Indisulam targets RNA splicing and metabolism to serve as a therapeutic strategy for high-risk neuroblastoma","volume":"13","author":"Nijhuis","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2026.118921_bib21","doi-asserted-by":"crossref","first-page":"8287","DOI":"10.1038\/s41467-025-63979-x","article-title":"RBM39 degrader invigorates innate immunity to eradicate neuroblastoma despite cancer cell plasticity","volume":"16","author":"Singh","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2026.118921_bib22","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1038\/s41467-022-29224-5","article-title":"Integrative multi-omics and drug response profiling of childhood acute lymphoblastic leukemia cell lines","volume":"13","author":"Leo","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2026.118921_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2023.113307","article-title":"Pharmacological depletion of RNA splicing factor RBM39 by indisulam synergizes with PARP inhibitors in high-grade serous ovarian carcinoma","volume":"42","author":"Xu","year":"2023","journal-title":"Cell Rep."},{"key":"10.1016\/j.ejmech.2026.118921_bib24","doi-asserted-by":"crossref","first-page":"5068","DOI":"10.1016\/j.cell.2023.09.011","article-title":"Arginine reprograms metabolism in liver cancer via RBM39","volume":"186","author":"Mossmann","year":"2023","journal-title":"Cell"},{"key":"10.1016\/j.ejmech.2026.118921_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.jcmgh.2024.101404","article-title":"RBM39 enhances cholangiocarcinoma growth through EZH2-mediated WNT7B\/\u03b2-catenin pathway","volume":"19","author":"Liu","year":"2025","journal-title":"Cell. Mol. Gastroenterol. Hepatol."},{"key":"10.1016\/j.ejmech.2026.118921_bib26","doi-asserted-by":"crossref","first-page":"4288","DOI":"10.1038\/s41467-021-24498-7","article-title":"Targeting KRAS4A splicing through the RBM39\/DCAF15 pathway inhibits cancer stem cells","volume":"12","author":"Chen","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2026.118921_bib27","doi-asserted-by":"crossref","first-page":"4032","DOI":"10.1016\/j.cell.2021.05.038","article-title":"Pharmacologic modulation of RNA splicing enhances anti-tumor immunity","volume":"184","author":"Lu","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.ejmech.2026.118921_bib28","doi-asserted-by":"crossref","first-page":"2795","DOI":"10.1111\/bph.15331","article-title":"RNA-binding motif protein 39 (RBM39): an emerging cancer target","volume":"179","author":"Xu","year":"2022","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ejmech.2026.118921_bib29","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1038\/s41420-021-00598-7","article-title":"RNA-binding protein 39: a promising therapeutic target for cancer","volume":"7","author":"Xu","year":"2021","journal-title":"Cell Death Discov."},{"key":"10.1016\/j.ejmech.2026.118921_bib30","doi-asserted-by":"crossref","first-page":"5538","DOI":"10.1021\/acs.jmedchem.3c02136","article-title":"Optimization of potent ligands for the E3 ligase DCAF15 and evaluation of their use in heterobifunctional degraders","volume":"67","author":"Lucas","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118921_bib31","doi-asserted-by":"crossref","first-page":"7807","DOI":"10.1021\/acs.jmedchem.5c00534","article-title":"Synthesis of an RBM39 degrader that downregulates CEP192 and induces disorganized spindle structures","volume":"68","author":"Lyu","year":"2025","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118921_bib32","series-title":"RBM39 Degrader for Biomarker-Enriched Solid Tumors and Lymphoma","article-title":"Recursion announces first patient dosed in phase 1\/2 clinical study of REC-1245, a potential first-in-class","year":"2024"},{"key":"10.1016\/j.ejmech.2026.118921_bib33","article-title":"Abstract 7035: targeting ewing sarcoma with a novel RBM39 degrader: DNA damage repair pathway effects","volume":"85","author":"Liu","year":"2025","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejmech.2026.118921_bib34","doi-asserted-by":"crossref","first-page":"3363","DOI":"10.1002\/cncr.34942","article-title":"Consensus recommendations in the management of ewing sarcoma from the national ewing Sarcoma tumor board","volume":"129","author":"Gupta","year":"2023","journal-title":"Cancer"},{"key":"10.1016\/j.ejmech.2026.118921_bib35","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.31917","article-title":"New approaches to investigate novel agents in ewing sarcoma: a report from the children's oncology group bone tumor committee","volume":"72","author":"Daley","year":"2025","journal-title":"Pediatr. Blood Cancer"},{"key":"10.1016\/j.ejmech.2026.118921_bib36","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1016\/j.str.2019.10.005","article-title":"Structural basis and kinetic pathway of RBM39 recruitment to DCAF15 by a sulfonamide molecular glue E7820","volume":"27","author":"Du","year":"2019","journal-title":"Structure"},{"key":"10.1016\/j.ejmech.2026.118921_bib37","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/0092-8674(95)90241-4","article-title":"Multiple proteolytic systems, including the proteasome, contribute to CFTR processing","volume":"83","author":"Jensen","year":"1995","journal-title":"Cell"},{"key":"10.1016\/j.ejmech.2026.118921_bib38","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/j.cell.2010.11.017","article-title":"Dynamics of cullin-RING ubiquitin ligase network revealed by systematic quantitative proteomics","volume":"143","author":"Bennett","year":"2010","journal-title":"Cell"},{"key":"10.1016\/j.ejmech.2026.118921_bib39","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1038\/nature07884","article-title":"An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer","volume":"458","author":"Soucy","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2026.118921_bib40","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1038\/s41375-020-0729-9","article-title":"Biomarkers for RBM39 degradation in acute myeloid leukemia","volume":"34","author":"Hsiehchen","year":"2020","journal-title":"Leukemia"},{"key":"10.1016\/j.ejmech.2026.118921_bib41","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1016\/j.celrep.2019.09.079","article-title":"Aryl sulfonamides degrade RBM39 and RBM23 by recruitment to CRL4-DCAF15","volume":"29","author":"Ting","year":"2019","journal-title":"Cell Rep."},{"key":"10.1016\/j.ejmech.2026.118921_bib42","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.bmcl.2003.09.062","article-title":"Carbonic anhydrase inhibitors: E7070, a sulfonamide anticancer agent, potently inhibits cytosolic isozymes I and II, and transmembrane, tumor-associated isozyme IX","volume":"14","author":"Abbate","year":"2004","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.ejmech.2026.118921_bib43","series-title":"Preparation of sulfonamide-containing Indole Derivatives as Inhibitors of Neovascularization and Tumor","author":"Haneda","year":"2000"},{"key":"10.1016\/j.ejmech.2026.118921_bib44","doi-asserted-by":"crossref","first-page":"5616","DOI":"10.1021\/acs.jmedchem.4c02884","article-title":"Selective degradation of TEADs by a PROTAC molecule exhibited robust anticancer efficacy in vitro and in vivo","volume":"68","author":"Lu","year":"2025","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118921_bib45","doi-asserted-by":"crossref","first-page":"16991","DOI":"10.1021\/acs.jmedchem.3c01815","article-title":"Discovery of JN122, a spiroindoline-containing molecule that inhibits MDM2\/p53 protein\u2013protein interaction and exerts robust in vivo antitumor efficacy","volume":"66","author":"Cheng","year":"2023","journal-title":"J. Med. Chem."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523426003661?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523426003661?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T02:28:09Z","timestamp":1783045689000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523426003661"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":45,"alternative-id":["S0223523426003661"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2026.118921","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Discovery and characterization of YSA64, a RBM39 degrader with in vivo efficacy and potent cellular activity in pediatric Ewing sarcoma A673","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2026.118921","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"118921"}}